Targeting Hexokinase 2 for Cancer Therapy: Advances, Limitations, and Emerging Opportunities in Inhibitors and Degraders

Xianglong Wang; Baohu Li; Wei-Wei Yao; Jinfei Yang

doi:10.1039/d6md00103c

January 1, 2026RSC Medicinal Chemistry

Targeting Hexokinase 2 for Cancer Therapy: Advances, Limitations, and Emerging Opportunities in Inhibitors and Degraders

View at Publisher

Ask AI

Bookmark

Share

Key Points

To assess the role of hexokinase 2 in cancer therapy and explore new strategies targeting this enzyme.
Reviewed recent strategies targeting hexokinase 2, including inhibitors and degraders.
Analyzed the limitations and effectiveness of current therapies aimed at HK2.
Identified several promising HK2 inhibitors that enhance cancer cell death.
Discussed limitations of existing therapies, indicating a need for novel approaches.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Review highlights advances in targeting hexokinase 2 in cancer metabolism, suggesting future therapeutic possibilities.

Abstract

Hexokinase 2 (HK2) is an important target in cancer metabolism because it supports both glycolytic flux and mitochondria-associated survival signaling. In recent years, multiple HK2-directed strategies have emerged, including active-site...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf6d7faef96ed7f05877d https://doi.org/10.1039/d6md00103c

View at Publisher

Ask AI

Bookmark

Share

Targeting Hexokinase 2 for Cancer Therapy: Advances, Limitations, and Emerging Opportunities in Inhibitors and Degraders

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Targeting Hexokinase 2 for Cancer Therapy: Advances, Limitations, and Emerging Opportunities in Inhibitors and Degraders

Key Points

Ask about this paper

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading